Non-human primate models for Parkinson's disease

Drug Discovery Today: Disease Models

Volumn 5, Issue 2, 2008, Pages 105-111

  Philippens, Ingrid H C H M ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AGRICULTURAL CHEMICAL; ALPHA 2C ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; BENSERAZIDE; CABERGOLINE; CARBIDOPA; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRONABINOL; LEVODOPA; LY 314582; MEMANTINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PRAMIPEXOLE; RESERPINE; UNCLASSIFIED DRUG;

DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EYE HAND COORDINATION; GENE MUTATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; INHERITANCE; LOCOMOTION; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIMATE; REVIEW; ROBOTICS; SUBSTANTIA NIGRA;

EID: 59249091811     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2008.06.004     Document Type: Review

References (44)

1. Parkinson J. An Essay on the Shaking Palsy (1817), Sherwood, Nealey and Wood
2. Ehringer H., and Hornykiewiczo O. Verteiling van Noradrenalin und Dopamin (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des Extrapyramidales Systems. Klin Wochenschr 38 (1960) 1236-1239
3. Gasser T. Genetics of Parkinson's disease. Curr. Opin. Neurol. 18 (2005) 363-369
4. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Move. Disord. 20 Suppl. 11 (2005) S11-S16
5. Nyholm D., et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin. Neurpharmacol. 31 (2008) 63-73
6. Deleu D., et al. An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease. Saudi Med. J. 23 (2002) 1165-1175
7. Fernandez H.H., and Chen J.J. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 12 (2007) 174S-185S
8. Tatton W.G., et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 301 (2002) 753-764
9. Lee C.S., et al. Inhibition of 1-methyl-4-phenylpyridinium-induced mitochondrial dysfunction and cell death in PC12 cells by sulfonylurea glibenclamide. Eur. J. Pharmacol. 527 (2005) 23-30
10. Lee C.S., et al. Piperine inhibition of 1-methyl-4-phenylpyridinium-induced mitochondrial dysfunction and cell death in PC12 cells. Eur. J. Pharmacol. 537 (2006) 37-44
11. Senoh S., et al. Enzymatic p-O-methylation by catechol O-methyl transferase. J Am. Chem. Soc. 81 (1959) 6240-6245
12. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J. Pharmacol. 5 (1968) 107-110
13. Heikkila R.E., and Cohen G. 6-Hydroxydopamine: evidence for superoxide radical as an oxidative intermediate. Science 181 (1972) 456-457
14. Annett L.E., et al. Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 115 (1992) 825-856
15. Morgan D.R. Experimental use of reserpine in the treatment of tremor-rigidity syndromes. Med. J. Aust. 43 (1956) 973-977
16. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
17. Langston J.W., et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
18. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Mol. Brain Res. 134 (2005) 57-66
19. Emborg M.E. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Meth. 139 (2004) 121-143
20. Schmidt N., and Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural. Transm. 108 (2001) 1263-1282
21. Water C.M., et al. An immunohostochemical study of the acute and long-term effects of 1-methyl-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Neuroscience 23 (1987) 1025-1039
22. Tatton W.G., et al. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res. 527 (1990) 21-31
23. Van Vliet S.A.M., et al. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res. 1189 (2008) 219-228
24. Gerlach M., et al. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208 (1991) 273-286
25. Di Monte D.A., et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 15 (2000) 459-466
26. Van Vliet S.A.M., et al. Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects. Behav. Pharmacol. 17 (2006) 453-462
27. Philippens I.H.C.H.M., et al. Behavioral test systems in marmoset monkeys. Behav. Res. Methods Instrum Comput. 32 (2000) 173-179
28. Przybyszewski A.W., et al. Quantification of three-dimensional exploration in the cylinder test by the common marmoset (Callithrix jacchus). Behav. Brain Res. 170 (2006) 62-70
29. Marshall J.W., and Ridley R.M. Assessment of functional impairment following permanent middle cerebral artery occlusion in a non-human primate species. Neurodegeneration 5 (1996) 275-286
30. Wolthuis O.L., et al. Effects of low doses of cholinesterase inhibitors on behavioral performance of robot-tested marmosets. Pharmacol. Biochem. Behav. 51 (1995) 443-456
31. Jenner P., and Marsden C.D. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. J. Neural. Transm. 20 (1986) 11-39
32. Wolthuis O.L., et al. A simple automated test to measure exploratory and motor activity of marmosets. Pharmacol. Biochem. Behav. 47 (1994) 879-881
33. Crossman A.R., et al. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology 28 (1989) 1271-1273
34. Hornykiewicz O., and Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45 (1987) 19-34
35. Marien M.R., et al. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 45 (2004) 38-78
36. Pertovaara A., et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev. 11 (2005) 273-288
37. Van Vliet S.A.M., et al. Therapeutic effects of Delta(9)-THC and modafinil in a marmoset Parkinson model. Eur. Neuropsychopharmacol. 18 (2008) 383-389
38. Forno L.S., et al. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20 (1986) 449-455
39. Purisai M.G., et al. α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol. Dis. 20 (2005) 898-906
40. Kirik D., et al. Nigrostriatal alpha-synucleinopathy induced by viral vectormediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 2884-2889
41. Fornai F., et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3413-3418
42. Przedborski S., et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety. J. Neurochem. 76 (2001) 1265-1274
43. Hardman C.D., et al. Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J. Compd. Neurol. 445 (2002) 238-255
44. Eslamboli A. Marmoset monkey models of Parkinson's disease: which model, when and why?. Brain Res. Bull. 68 (2005) 140-149